Medical Learning Hub (MLH) welcomes you to recorded live clinical experience sharing on Topic: " Complex case management in treating COVID-19 patients ".
Module 1: Clinical experience sharing in treating adults, use of Remdesivir: Dr. Bharti Wadhwa (10.55)
• How corona virus infects and replicates in human body explained 
• Remdesivir and COVID-19 - How does Remdesivir work explained 
• Clinical management protocol - COVID -19 and protocol for use of Remdesivir discussed 
• Selection of patient and treatment initiated explained 
• Hepatic impairment and Remdesivir discussed 
• Renal impairment and Remdesivir use discussed 
• Consent before initiated before use of Remdesivir 
• Preparation and administration on Remdesivir explained 
• Treatment duration and dosage of Remdesivir 
• When to discontinue Remdesivir in COVID-19 patient discussed
• Side effects and drug interaction of Remdesivir 
• Controversy over Use of Remdesivir discussed 
• Comparison of WHO and ACTT-1 trail and why FDA approved use of Remdesivir discussed 
• The different trails and conflicting results on use of Remdesivir discussed 
• Personal clinical experience with use of Remdesivir shared 
• Barcitinib as newer combination Drug with Remdesivir discussed 
• Conclusion on role and use of Remdesivir explained
Module 2: Comorbidities and Outcome in COVID-19 patients. Nikhil Modi (44.50)
• Comorbidities: Complications and poor outcomes discussed 
o Cancer and outcomes discussed 
o Diabetes and C0VID-19 discussed 
o Renal disease and outcome discussed 
o Sickle cell disease and Transplant pts 
o Gender and age-related outcomes discussed 
o Poor outcomes less in patients with asthma explained 
o Discussion on outcomes in patients with multiple comorbidities 
o Cardiac patients and COVID outcome discussed 
o Data at hospital ICU on comorbidities and outcome discussed 
o Outcomes in renal transplant patients discussed 
o Reason and role of comorbidities for causing poor outcomes
(decreased immune response, delayed immune response in diabetic and oncology patients) 
o Importance of using Remdesivir in patients with comorbidities
Module 3: Case Presentations and clinical experience sharing: Dr. Vaibhav Shankar (1.04.00)
• Disease progression, investigation, management and prognosis of cases discussed. The cases selected were 
o The case with prolonged COVID-19 lung complication 
o Immunocompromised patient 
o Patient with cardiac involvement 
o Morbidly obese patient 
• Conclusion and interferences observed discussed
Module 4: Question Answer section (1.21.00)
We thank our sponsors Viatris to make this program possible and we wish you a great learning experience.